Skip to Content

Insulin Glargine and Lixisenatide

Pronunciation

(IN soo lin GLAR jeen & lix i SEN a tide)

Index Terms

  • Lixisenatide and Insulin Glargine
  • Soliqua

Pharmacologic Category

  • Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
  • Insulin, Long-Acting

Use: Labeled Indications

Diabetes mellitus, type 2: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (<60 units daily) or lixisenatide

Limitations of use: Has not been studied in patients with a history of pancreatitis; not recommended for use in combination with any other product containing lixisenatide or another GLP-1 receptor agonist; not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis; has not been studied in combination with prandial insulin

Contraindications

Hypersensitivity to insulin glargine, lixisenatide, or any component of the formulation; during episodes of hypoglycemia

Hide